DYN Dyne Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: DYN

Price (delayed)

$11.44

Market cap

$702.14M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.58

Enterprise value

$597.76M

Dyne Therapeutics, Inc. operates as a biotechnology company. The Company focuses on transforming the lives of people with serious diseases by developing muscle-targeted therapies. Dyne Therapeutics offers its services in ...

Highlights
The debt is down by 9% year-on-year and by 2.8% since the previous quarter
Dyne Therapeutics's quick ratio has decreased by 49% YoY and by 48% from the previous quarter
The equity has contracted by 39% YoY and by 27% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.dyne-tx.com
Peers: NRG AES ALE CNP

Key stats

What are the main financial stats of DYN
Market
Shares outstanding
61.38M
Market cap
$702.14M
Enterprise value
$597.76M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.59
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$208.13M
EBITDA
-$205.62M
Free cash flow
-$183.51M
Per share
EPS
-$3.58
Free cash flow per share
-$3
Book value per share
$2.49
Revenue per share
$0
TBVPS
$3.36
Balance sheet
Total assets
$205.24M
Total liabilities
$53.21M
Debt
$28.23M
Equity
$152.04M
Working capital
$138.52M
Liquidity
Debt to equity
0.19
Current ratio
5.67
Quick ratio
5.39
Net debt/EBITDA
0.51
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-79.2%
Return on equity
-97.6%
Return on invested capital
-203.5%
Return on capital employed
-118.6%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DYN stock price

How has the Dyne Therapeutics stock price performed over time
Intraday
-2.05%
1 week
4.09%
1 month
40.2%
1 year
1.51%
YTD
-1.29%
QTD
27.68%

Financial performance

How have Dyne Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$214.62M
Net income
-$208.13M
Gross margin
N/A
Net margin
N/A
DYN's operating income is down by 17% YoY and by 10% QoQ
DYN's net income is down by 15% YoY and by 10% QoQ

Growth

What is Dyne Therapeutics's growth rate over time

Valuation

What is Dyne Therapeutics stock price valuation
P/E
N/A
P/B
4.59
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
DYN's EPS is down by 6% since the previous quarter
The price to book (P/B) is 56% higher than the last 4 quarters average of 3.0
The equity has contracted by 39% YoY and by 27% from the previous quarter

Efficiency

How efficient is Dyne Therapeutics business performance
DYN's return on invested capital has dropped by 139% year-on-year and by 35% since the previous quarter
The return on equity has dropped by 67% year-on-year and by 23% since the previous quarter
The company's return on assets has shrunk by 59% YoY and by 20% QoQ

Dividends

What is DYN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DYN.

Financial health

How did Dyne Therapeutics financials performed over time
Dyne Therapeutics's current ratio has decreased by 49% YoY and by 46% from the previous quarter
Dyne Therapeutics's quick ratio has decreased by 49% YoY and by 48% from the previous quarter
The debt is 81% smaller than the equity
Dyne Therapeutics's debt to equity has surged by 58% YoY and by 36% QoQ
The equity has contracted by 39% YoY and by 27% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.